Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, announces the start of the THULITE phase II clinical study (NCT06962839). It will investigate the efficacy, ...
The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to reduce fluid leakage in the retina and ease the treatment burden for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results